Patents Examined by Irina Neagu
  • In situ generation of peroxycarboxylic acids at alkaline pH, and methods of use thereof
    Patent number: 10477862
    Abstract: The present disclosure is related to percarboxylic acid compositions formed in situ in non-equilibrium reactions. The peroxycarboxylic acid compositions are formed using ester based starting materials. Methods for using the percarboxylic acid compositions are also disclosed.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: November 19, 2019
    Assignee: Ecolab USA Inc.
    Inventors: Junzhong Li, David D. McSherry, Richard Staub
  • Sorafenib derivatives as p21 inhibitors
    Patent number: 10449182
    Abstract: The present invention provides sorafenib analogs for use in a method of treating a disease mediated by p21, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I. The present invention also provides methods of inhibiting p21 in a cell comprising contacting the cell with an effective amount of a compound of formula I.
    Type: Grant
    Filed: June 20, 2013
    Date of Patent: October 22, 2019
    Assignee: The Regents of the University of California
    Inventors: Robert H. Weiss, Bruce D. Hammock, Hiromi Inoue Wettersten, Sung Hee Hwang
  • Method of using an indolinone molecule and derivatives for inhibiting liver fibrosis and hepatitis
    Patent number: 10450295
    Abstract: This invention relates to methods of reversing and inhibiting liver fibrosis and hepatitis using a small indolinone molecule Hesperadin and related compounds. Methods of identifying such agents and using them to inhibit the expression of collagens and ECM proteins including MMPs and TIMPs in purified hepatic stellate cells are provided. In vivo data of Hesperadin in inhibiting induced collagen production are presented. This method of specifically targeting drugs to hepatic stellate cells in vivo, provides a novel therapy for liver diseases.
    Type: Grant
    Filed: August 9, 2013
    Date of Patent: October 22, 2019
    Assignee: Acclaim BioMed USA LLC
    Inventors: Kenneth Ka-Ho Lee, Stanton Hon-Lung Kok, Tsz-Wai Kok, Sing-Wan Wong, John Yeuk-Hon Chan
  • Pharmaceutical composition containing Ginkgolide B and blood platelet prostaglandin cyclooxygenase inhibitor and method for preparation thereof and use thereof
    Patent number: 10441599
    Abstract: Provided is a pharmaceutical composition containing ginkgolide B and the blood platelet prostaglandin cyclooxygenase inhibitor aspirin, a method for preparation of the pharmaceutical composition and a use thereof. When used together, ginkgolide B and aspirin have a synergistic effect in resisting platelet aggregation.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: October 15, 2019
    Assignee: CHENGDU BAIYU PHARMACEUTICAL CO., LTD
    Inventor: Yi Sun
  • Compounds
    Patent number: 10435391
    Abstract: The present invention relates to compounds, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of RIP2 kinase, including degrading RIP2 kinase, the treatment of diseases and conditions mediated by the RIP2 kinase, in particular for the treatment of inflammatory diseases or conditions.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: October 8, 2019
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Linda N. Casillas, John David Harling, Afjal Hussain Miah, Mark David Rackham, Ian Edward David Smith
  • Crystalline forms of darunavir
    Patent number: 10407438
    Abstract: The present invention relates to novel crystalline forms of darunavir, the pharmaceutical formulations, and the therapeutic uses thereof in treating viral infections.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: September 10, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Chiajen Lai, Bing Shi
  • Methods and compositions to treat cancer
    Patent number: 10391084
    Abstract: Embodiments provided herein relate to methods and compositions for treating cancer. Some embodiments include treating lung cancers and renal cancers.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: August 27, 2019
    Assignee: Children's Hospital Medical Center
    Inventors: Jeffrey Whitsett, Yutaka Maeda
  • Carbazole-containing sulfonamides as cryptochrome modulators
    Patent number: 10383880
    Abstract: The subject matter herein is directed to carbazole-containing sulfonamide derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R1, R2, R3, R4, R5, R6, R7, A, B, C?, D, E, F, G, H?, a, and b are accordingly described. Also provided are pharmaceutical compositions comprising the compounds of formula I to treat a Cry-mediated disease or disorder, such as diabetes, obesity, metabolic syndrome, Cushing's syndrome, and glaucoma.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: August 20, 2019
    Assignee: Synchronicity
    Inventors: Ross Bersot, Paul Humphries
  • Aqueous composition containing ripasudil, or a salt, or a solvate thereof
    Patent number: 10376523
    Abstract: An aqueous composition having an excellent antiseptic effect is provided. An aqueous composition containing: a compound represented by Formula (1), a salt thereof, or a solvate of the compound or the salt thereof, where X represents a halogen atom, and a quaternary ammonium surfactant. A method for producing an aqueous composition with an antiseptic effect, by incorporating a compound represented by Formula (1), a salt thereof, or a solvate of the compound or the salt thereof and a quaternary ammonium surfactant into the aqueous composition.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: August 13, 2019
    Assignee: KOWA COMPANY, LTD.
    Inventor: Shin Sugimoto
  • Isoflavonoid compositions and methods for the treatment of cancer
    Patent number: 10369132
    Abstract: Provided herein is a pharmaceutical composition comprising an isoflavonoid derivative and a cyclodextrin. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions. In specific instances, provided herein are intravenous compositions and therapies.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: August 6, 2019
    Assignee: MEI PHARMA, INC.
    Inventor: Ofir Moreno
  • Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
    Patent number: 10363236
    Abstract: An isothiocyanate functional surfactant, wherein the protonated form of said surfactant is represented by the following chemical structure: wherein X includes an integer ranging from approximately 1 to approximately 25, and wherein Y includes an integer ranging from approximately 6 to approximately 25.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: July 30, 2019
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
    Patent number: 10343990
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of keratin-based skin diseases. In particular, the application describes compositions and methods of treating a patient suffering from skin blistering comprising the use of phase II enzyme inducers and/or activity modifiers.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: July 9, 2019
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Methods and compositions for treating metabolic syndrome
    Patent number: 10335418
    Abstract: Provided are methods, compositions, systems, and kits for treating metabolic syndrome or a disorder associated with metabolic syndrome, e.g., obesity, dyslipidemia, and/or a diabetic condition, comprising administering systemically to a subject one or more compounds of the Formula (I) and/or (II): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, polymorph, tautomer, isotopically enriched derivative, or prodrug thereof, wherein , L, R1, R2, Z, X, A and B are defined herein.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: July 2, 2019
    Assignee: Topokine Therapeutics, Inc.
    Inventor: Murat V. Kalayoglu
  • Formulations for solubilizing hormones
    Patent number: 10328087
    Abstract: Compositions and methods for the solubilization of steroid hormones are disclosed.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: June 25, 2019
    Assignee: TherapeuticsMD, Inc.
    Inventors: Thorsteinn Thorsteinsson, Frederick D. Sancilio, Brian A. Bernick, Julia M. Amadio
  • Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant
    Patent number: 10328028
    Abstract: The present invention relates to a pharmaceutical composition comprising amorphous lenalidomide, or a pharmaceutically acceptable salt thereof, with a synthetic antioxidant and one or more pharmaceutically acceptable excipients. The invention further relates to the process to manufacture such a compositions and the use of said composition as a medicament, particularly in the treatment of in the treatment of multiple myeloma and myelodyplastic syndromes.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: June 25, 2019
    Assignee: Synthon B.V.
    Inventors: Marta Vivancos Martinez, Lisardo Alvarez Fernandez, Jose Velada Calzada
  • Methods and compositions for treating degenerative and ischemic disorders
    Patent number: 10322122
    Abstract: Model systems have shown that shifting a cell's reliance from oxidative phosphorylation (OXPHOS) to glycolysis can protect against cell death. Exploiting the therapeutic potential of this strategy, however, has been limited by the lack of clinically safe agents that remodel energy metabolism. The present invention identifies non-toxic small molecules (e.g., drug-like compounds) that are capable of modulating oxidative metabolism. One identified compound comprises meclizine. As described herein, meclizine, and its enantiomer S-meclizine, redirects OXPHOS to glycolysis. Such compounds could be protective or therapeutic in degenerative disorders such as diabetes, Huntington's, Parkinson's, and Alzheimer's disease and/or ischemic disorders including, but not limited to, stroke, heart attack, or reperfusion injuries.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: June 18, 2019
    Assignee: The General Hospital Corporation
    Inventors: Vamsi K. Mootha, Vishal Gohil, Sunil Sheth, Yuhua Ji
  • Oral suspension comprising telmisartan
    Patent number: 10314782
    Abstract: A pharmaceutical solution with a pH value of 10 or higher contains an angiotensin II receptor antagonist, where one or more sugar alcohols are present up to a total concentration of 40 wt. % to 70 wt. %.
    Type: Grant
    Filed: August 27, 2014
    Date of Patent: June 11, 2019
    Assignee: BOEHRINGER INGELHEIM VETMEDICA GMBH
    Inventors: Detlef Mohr, Stefan Lehner
  • Compositions and methods for treatment of prostate cancer
    Patent number: 10307401
    Abstract: The present invention relates to compositions and methods for the treatment of prostate cancer. The present invention relates to polyamides and prostate agents, for example, to inhibit an androgen receptor signaling axis, and the use of these compositions in the treatment of prostate cancer.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: June 4, 2019
    Assignee: California Institute of Technology
    Inventors: Peter B. Dervan, Nickolas G. Nickols, Fei Yang, Alexis A. Kurmis
  • Isothiocyanate functional surfactant and associated method of use
    Patent number: 10308600
    Abstract: A method for treating phytophotodermatitis including the steps of applying an isothiocyanate functional surfactant to an area affected by phytophotodermatitis, wherein said isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: June 4, 2019
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Tetrahydropyridopyrimidine compound or salt thereof
    Patent number: 10300067
    Abstract: A method for inhibiting androgen activity, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof, and a method for treating tumor, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: May 28, 2019
    Assignee: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Kazuhisa Minamiguchi, Shigeo Okajima, Shinichi Aoki, Masanori Asai, Takahiro Asai, Hiroyoshi Yamanaka, Suguru Dohi